Orchard Therapeutics announces agreement with the Beneluxa Consortium enabling reimbursed access to Libmeldy (atidarsagene autotemcel for early-onset metachromatic leukodystrophy.
Orchard Therapeutics, announced the company has reached an agreement with the Beneluxa Initiative on Pharmaceutical Policy (Beneluxa) enabling reimbursed access to Libmeldy (atidarsagene autotemcel), a hematopoietic stem cell (HSC) gene therapy, approved for the treatment of early-onset metachromatic leukodystrophy (MLD)
The agreement covers several member countries, including Belgium, The Netherlands, and Ireland. It follows similar arrangements made with reimbursement authorities in the United Kingdom (UK), Italy, Germany, Sweden, Iceland, Finland and Norway, and is a key component of the company’s geographic expansion plans.
Multiple eligible MLD patients are currently in the treatment process and expected to receive Libmeldy in the coming months. This includes the first patient treated at the company’s qualified center in Utrecht, The Netherlands. Following administration, patients will have been treated at all six of the company’s initially qualified treatment centers in Europe. Additional centers in Spain and Saudi Arabia are currently in the final stages of qualification and are expected to be ready to treat MLD patients with Libmeldy in the near future.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins